MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE

Antibody-drug conjugates that bind to human oncology targets are disclosed. The antibody-drug conjugates comprise an Mcl-1 inhibitor drug moiety. The disclosure further relates to methods and compositions for use in the treatment of cancers by administering the antibody-drug conjugates provided here...

Full description

Saved in:
Bibliographic Details
Main Authors Geneste, Olivier, Kostova, Vesela, D'Alessio, Joseph Anthony, Colland, Frédéric, Nakajima, Katsumasa, Delacour, Lea, Csekei, Marton, Chen, Zhuoliang, Chanrion, Maia, Yu, Bing, Palermo, Mark G, Desos, Patrice, Kotschy, Andras, Proszenyák, Ágnes, Rocchetti, Francesca, Maragno, Ana Leticia, McNeill, Eric, Sipos, Szabolcs, Zhang, Qiang, Henlin, Jean-Michel, Burger, Matthew T, Starck, Jérôme
Format Patent
LanguageEnglish
Published 23.03.2023
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Antibody-drug conjugates that bind to human oncology targets are disclosed. The antibody-drug conjugates comprise an Mcl-1 inhibitor drug moiety. The disclosure further relates to methods and compositions for use in the treatment of cancers by administering the antibody-drug conjugates provided herein. Linker-drug conjugates comprising an Mcl-1 inhibitor drug moiety and methods of making same are also disclosed.
Bibliography:Application Number: US202017613006